FHTX vs. ME, VERU, CDT, ACIU, ALDX, HOWL, EBS, QURE, PBYI, and ZVRA
Should you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include 23andMe (ME), Veru (VERU), Conduit Pharmaceuticals (CDT), AC Immune (ACIU), Aldeyra Therapeutics (ALDX), Werewolf Therapeutics (HOWL), Emergent BioSolutions (EBS), uniQure (QURE), Puma Biotechnology (PBYI), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical preparations" industry.
23andMe (NASDAQ:ME) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Foghorn Therapeutics has lower revenue, but higher earnings than 23andMe. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
36.1% of 23andMe shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 27.6% of 23andMe shares are held by company insiders. Comparatively, 9.2% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
23andMe has a net margin of -210.48% compared to 23andMe's net margin of -288.17%. 23andMe's return on equity of 0.00% beat Foghorn Therapeutics' return on equity.
23andMe currently has a consensus price target of $0.47, indicating a potential downside of 4.59%. Foghorn Therapeutics has a consensus price target of $14.50, indicating a potential upside of 137.32%. Given 23andMe's stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than 23andMe.
Foghorn Therapeutics received 20 more outperform votes than 23andMe when rated by MarketBeat users. However, 63.16% of users gave 23andMe an outperform vote while only 59.26% of users gave Foghorn Therapeutics an outperform vote.
23andMe has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500.
In the previous week, Foghorn Therapeutics had 11 more articles in the media than 23andMe. MarketBeat recorded 19 mentions for Foghorn Therapeutics and 8 mentions for 23andMe. Foghorn Therapeutics' average media sentiment score of 0.49 beat 23andMe's score of 0.04 indicating that 23andMe is being referred to more favorably in the media.
Summary
Foghorn Therapeutics beats 23andMe on 11 of the 18 factors compared between the two stocks.
Get Foghorn Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Foghorn Therapeutics Competitors List
Related Companies and Tools
